- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Summer 2012

Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
Teva Pharma. USA Inc. v. Synthon Pharma., Inc., 12-2556 (S.D.N.Y.) |
Apr. 3, 2012 |
Hon. Barbara S. Jones |
Copaxone®(glatiramer acetate injection) |
7,199,098 6,939,539 6,054,430 6,620,847 5,981,589 6,342,476 6,362,161 |
AR Holding Co., Inc. v. Par Pharma., Inc., 12-0419 (D. Del.) |
Apr. 4, 2012 |
Hon. Mary Pat Thynge |
Colcrys®(colchicine USP) |
7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,964,648 7,981,938 8,093,296 8,093,297 8,097,655 |
Teva Pharma. USA, Inc. v. Synthon Pharma., Inc., 12-0179 (E.D.N.C.) |
Apr. 4, 2012 |
Hon. James C. Dever, III |
Copaxone®(glatiramer acetate injection) |
7,199,098 6,939,539 6,054,430 6,620,847 5,981,589 6,342,476 6,362,161 |
Allergan Sales, LLC v. Akorn, Inc., 12-0175 (E.D. Tex.) |
Apr. 4, 2012 |
Hon. Rodney Gilstrap |
Acular LS®(ketorolac tromethamine ophthalmic solution, 0.4%) |
8,008,338 |
Allergan Sales, LLC v. Alcon Research, Ltd., 12-0177 (E.D. Tex.) |
Apr. 4, 2012 |
Hon. Rodney Gilstrap |
Acular LS®(ketorolac tromethamine ophthalmic solution, 0.4%) |
8,008,338 |
Allergan Sales, LLC v. Apotex, Inc., 12-0178 (E.D. Tex.) |
Apr. 4, 2012 |
Hon. Rodney Gilstrap |
Acular LS®(ketorolac tromethamine ophthalmic solution, 0.4%) |
8,008,338 |
Sanofi-Aventis U.S. LLC v. Strides, Inc., 12-2070 (D.N.J.) |
Apr. 5, 2012 |
Hon. Joel A. Pisano |
Eloxatin®(oxaliplatin injection) |
5,338,874 5,716,988 |
Abbott Labs. v. Roxane Labs., Inc., 12-0457 (D. Del.) |
Apr. 10, 2012 |
Hon. Christopher J. Burke |
Norvir®(ritonavir tablets) |
7,148,359 7,364,752 5,648,497 |
Depomed, Inc. v. Impax Labs., Inc., 12-2154 (D.N.J.) |
Apr. 10, 2012 |
Hon. Joel A. Pisano |
Gralise®(gabapentin tablets) |
6,340,475 6,488,962 6,635,280 6,723,340 7,438,927 7,731,989 |
Roxane Labs., Inc., v. Abbott Labs., 12-0312 (S.D. Ohio) |
Apr. 10, 2012 |
Hon. Michael H. Watson |
Norvir®(ritonavir tablets) |
7,148,359 7,364,752 |
Purdue Pharma L.P. v. Varam, Inc., 12-2814 (S.D.N.Y.) |
Apr. 10, 2012 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended release tablets) |
5,508,042 7,674,799 7,674,800 7,683,072 |
AstraZeneca Pharma. LP v. IntelliPharmaCeutics Corp., 12-2855 (S.D.N.Y.) |
Apr. 11, 2012 |
Hon. Richard J. Sullivan |
Seroquel XR®(quetiapine fumurate extended release tablets) |
5,948,437 |
UCB, Inc. v. Mallinckrodt, Inc., 12-0463 (D. Del.) |
Apr. 12, 2012 |
Hon. Leonard P. Stark |
Metadate CD®(methylphenidate hydrochloride capsules) |
6,344,215 |
Purdue Pharma L.P. v. Varam, Inc., 12-1898 (E.D. Pa.) |
Apr. 12, 2012 |
Hon Petrese B. Tucker |
OxyContin®(oxycodone hydrochloride extended release tablets) |
5,508,042 7,674,799 7,674,800 7,683,072 |
Osi Pharma., LLC v. Roxane Labs., Inc., 12-0465 (D. Del.) |
Apr. 13, 2012 |
Hon. Sue L. Robinson |
Tarceva®(erlotinib hydrochloride tablets) |
RE41,065 6,900,221 7,087,613 |
Pfizer, Inc. v. Dr. Reddy’s Labs., Ltd., 12-0467 (D. Del.) |
Apr. 13, 2012 |
Hon. Leonard P. Stark |
Caduet®(amlodipine besylate and atorvastatin calcium tablets) |
6,455,574 |
Allergan, Inc. v. Sandoz, Inc., 12-0207 (E.D. Tex.) |
Apr. 13, 2012 |
Hon. Rodney Gilstrap |
Combigan®(brimonidine tartrate/timolol maleate ophthalmic solution, 0.2%/0.5%) |
8,133,890 |
Purdue Pharma L.P. v. Mylan Pharma. Inc., 12-2959 (S.D.N.Y.) |
Apr. 13, 2012 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended release tablets) |
7,674,799 7,674,800 7,683,072 |
Eli Lilly & Co. v. Apotex, Inc. 12-0499 (S.D. Ind.) |
Apr. 17, 2012 |
Hon. Jane Magnus-Stinson |
Alimta®(pemetrexed disodium injection) |
7,772,209 |
Depomed, Inc. v. Watson Labs., Inc. - Florida, 12-0492 (D. Del.) |
Apr. 18, 2012 |
Hon. Sue L. Robinson |
Glumetza®(metformin hydrochloride extended release tablets) |
6,488,962 7,780,987 |
Genzyme Corp. v. InvaGen Pharma., Inc., 12-1931 (E.D.N.Y.) |
Apr. 19, 2012 |
Hon. Margo K. Brodie |
Renvela®(sevelamer carbonate tablets ) |
5,667,775 |
Purdue Pharma L.P. v. Watson Labs., Inc. – Florida, 12-3111 (S.D.N.Y.) |
Apr. 19, 2012 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended release tablets) |
8,114,383 |
Apotex, Inc. v. Mylan Pharma., Inc., 12-60704 (S.D. Fla.) |
Apr. 20, 2012 |
Hon. Kathleen M. Willia ms |
Quinapril (quinapr il hydrochloride and hydrochlorothiazide) |
6,531,486 |
Apotex, Inc. v. Mylan Pharma., Inc., 12-60704 (S.D. Fla.) |
Apr. 20, 2012 |
Hon. Kathleen M. Williams |
quinapril hydrochloride quinipril hydrochloride and hydrochlorothiazide |
6,531,486 |
Apotex, Inc. v. Pfizer, Inc., 12-60705 (S.D. Fla.) |
Apr. 20, 2012 |
Hon. K. Michael Moore |
Accupril®(quinapril) Accuretic®(hydrochlorothiazide and quinapril) |
6,531,486 |
Apotex, Inc. v. UCB, Inc., 12-60706 (S.D. Fla.) |
Apr. 20, 2012 |
Hon. Kathleen M. Williams |
Univasc®(moexipril) Uniretic®(moexipril HCl and hydrochlorothiazide) |
6,767,556 |
Apotex, Inc. v. Paddock Labs., Inc., 12-60707 (S.D. Fla.) |
Apr. 20, 2012 |
Hon. K. Michael Moore |
moexipril moexipril HCl and hydrochlrorthiazide |
6,767,556 |
Apotex, Inc. v. Lupin Pharma., Inc., 12-60708 (S.D. Fla.) |
Apr. 20, 2012 |
Hon. Donald M. Middlebrooks |
quinapril hydrochloride |
6,531,486 |
Genzyme Corp. v. Cobrek Pharma., Inc., 12-2937 (N.D. Ill.) |
Apr. 20, 2012 |
Hon. Milton I. Shadur |
Hectorol®(doxercalciferol injection) |
5,602,116 |
Osi Pharma., LLC v. Roxane Labs., Inc., 12-2384 (D.N.J.) |
Apr. 20, 2012 |
Hon. Dennis M. Cavanaugh |
Tarceva®(erlotinib hydrochloride tablets) |
RE41,065 6,900,221 7,087,613 |
Bayer Pharma AG v. Watson Pharma., Inc., 12-0517 (D. Del.) |
Apr. 25, 2012 |
Hon. Gregory M. Sleet |
Staxyn®(vardenafil HCl orally disintegrating tablets) |
6,362,178 7,696,206 |
Abbott Labs. V. Agila Specialties Private Ltd., 12-0520 (D. Del.) |
Apr. 25, 2012 |
Hon. Gregory M. Sleet |
Zemplar®(paricalcitol injection) |
6,136,799 6,361,758 5,597,815 |
Orion Corp. v. Mylan Pharma., Inc., 12-0523 (D. Del.) |
Apr. 26, 2012 |
Hon. Gregory M. Sleet |
Stalevo®(carbidopa, levodopa, and entacapone tablets) |
5446194 6500867 6797732 |
Warner Chilcott Co., LLC v. Ranbaxy, Inc., 12-2474 (D.N.J.) |
Apr. 26, 2012 |
Hon. Faith S. Hochberg |
Atelvia®(risedronate sodium delayed release tablets) |
7,645,459 7,645,460 |
Otsuka Pharma. Co., Ltd. v. Amneal Pharma., LLC, 12-2487 (D.N.J.) |
Apr. 26, 2012 |
Hon. Mary L. Cooper |
Abilify®(aripiprazole oral solution) |
6,977,257 |
Teva Neuroscience, Inc. v. Sandoz Inc., 12-2494 (D.N.J.) |
Apr. 26, 2012 |
Hon. Claire C. Cecchi |
Azilect®(rasagiline mesylate tablets) |
5,453,446 |
Valeant International (Barbados) SRL v. Sandoz, Inc., 12-0536 (D. Del.) |
Apr. 30, 2012 |
Hon. Sherry R. Fallon |
Aplenzin®(bupropion hydrobromide extended release tablets) |
7,241,805 7,569,610 7,572,935 7,585,897 7,645,802 7,649,019 7,662,407 7,671,094 7,553,992 |
Shire Development LLC v. Watson Pharma., Inc., 12-60862 (S.D. Fla.) |
May 8, 2012 |
Hon. Donald M. Middlebrooks |
Lialda®(mesalamine delayed release tablets) |
6,773,720 |
Depomed, Inc. v. Zydus Pharma. (USA), Inc., 12-2813 (D.N.J.) |
May 9, 2012 |
Hon. Joel A. Pisano |
Gralise®(gabapentin tablets) |
6,340,475 6,488,962 6,635,280 6,723,340 7,438,927 7,731,989 |
Janssen Products, L.P. v. Lupin Ltd., 12-2840 (D.N.J.) |
May 10, 2012 |
Hon. William H. Walls |
Prezista®(darunavir tablets) |
RE42,889 |
Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd., 12-2867 (D.N.J.) |
May 11, 2012 |
Hon. Mary L. Cooper |
Aloxi®(palonosetron hydrochloride intravenous solutions) |
7,947,724 |
Novartis Pharma. Corp. v. Lupin Ltd., 12-0595 (D. Del.) |
May 14, 2012 |
Hon. Sue L. Robinson |
Exforge HCT®(amlodipine besylate, valsartan, and hydrochlorothiazide tablets) |
6,294,197 8,101,599 |
Novartis Pharma. Corp. v. Torrent Pharma. Ltd., 12-0596 (D. Del.) |
May 14, 2012 |
Hon. Sue L. Robinson |
Exforge HCT®(amlodipine besylate, valsartan, and hydrochlorothiazide tablets) |
6,294,197 8,101,599 |
Warner Chilcott Co., LLC v. Watson Labs., Inc., 12-2928 (D.N.J.) |
May 16, 2012 |
Hon. Joel A. Pisano |
Lo Loestrin®Fe (norethindrone acetate and ethinyl estradiol tablets) |
5,552,394 7,704,984 |
Allergan, Inc. v. Hi-Tech Pharmacal Co., Inc., 12-0492 (M.D.N.C.) |
May 16, 2012 |
Hon. Catherine C. Eagles |
Latisse®(bimatoprost topical solution, 0.03%) |
8,101,161 |
Cumberland Pharma. Inc. v. Innopharma, Inc., 12-0618 (D. Del.) |
May 17, 2012 |
Hon. Leonard P. Stark |
Acetadote®(acetylcysteine for injection) |
8,148,356 |
Cumberland Pharma. Inc. v. Paddock Labs., LLC, 12-0619 (D. Del.) |
May 17, 2012 |
Hon. Leonard P. Stark |
Acetadote®(acetylcysteine for injection) |
8,148,356 |
Cumberland Pharma. Inc. v. Mylan Institutional LLC, 12-3846 (N.D. Ill.) |
May 17, 2012 |
Hon. Rebecca R. Pallmeyer |
Acetadote®(acetylcysteine for injection) |
8,148,356 |
Janssen Pharma., Inc. v. Haupt Pharma., Inc., 12-3034 (D.N.J.) |
May 22, 2012 |
Hon. Stanley R. Chessler |
Ortho Tri-Cyclen®LO (norgestimate and ethinyl estradiol) |
6,214,815 |
Astellas US LLC v. Hospira, Inc., 12-0652 (D. Del.) |
May 23, 2012 |
Hon. Sue L. Robinson |
Adenoscan®(adenosine for injection) |
5,731,296 |
Auxilium Pharma., Inc. v. Watson Labs., Inc. (NV), 12-3084 (D.N.J.) |
May 23, 2012 |
Hon. Jose L. Linares |
Testim®(testosterone gel) |
7,320,968 7,608,605 7,608,606 7,608,607 7,608,608 7,608,609 7,608,610 7,935,690 8,063,029 8,178,518 |
Pfizer Inc. v. Sandoz Inc., 12-0654 (D. Del.) |
May 24, 2012 |
Hon. Gregory M. Sleet |
Torisel®(temsirolimus for injection) |
8,026,276 |
Shire Development, LLC v. Mylan Pharma., Inc., 12-1190 (M.D. Fla.) |
May 25, 2012 |
Hon. James S. Moody, Jr. |
Lialda®(mesalamine delayed release tablets) |
6,773,720 |
Merck Sharp & Dohme Corp. v. Sandoz Inc., 12-3289 (D.N.J.) |
May 31, 2012 |
Hon. Peter G. Sheridan |
Emend®(fosaprepitant dimeglumine for injection) |
5,691,336 5,716,942 |
Merck Sharp & Dohme Corp. v. Accord Healthcare, Inc. USA, 12-3324 (D.N.J.) |
June 1, 2012 |
Hon. Peter G. Sheridan |
Emend®(fosaprepitant dimeglumine for injection) |
5,691,336 5,716,942 |
Abbott Labs. v. Kremers Urban Pharma., Inc., 12-0703 (D. Del.) |
June 1, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended release tablets) |
6,080,428 6,469,035 |
Medicis Pharma. Corp. v. Zydus Pharma. USA Inc., 12-0707 (D. Del.) |
June 4, 2012 |
Hon. Leonard P. Stark |
Solodyn®(minocycline HCl extended release tablets) |
5,908,838 7,790,705 7,919,483 |
Medicis Pharma. Corp. v. Zydus Pharma. USA Inc., 12-3368 (D. Del.) |
June 5, 2012 |
Hon. Freda L. Wolfson |
Solodyn®(minocycline HCl extended release tablets) |
5,908,838 7,790,705 7,919,483 |
Janssen Products, L.P. v. Teva Pharma. USA, Inc., 12-3569 (D.N.J.) |
June 13, 2012 |
Hon. William H. Walls |
Prezista®(darunavir) |
RE42,889 |
Janssen Products, L.P. v. Hetero Drugs, Ltd., 12-3570 (D.N.J.) |
June 13, 2012 |
Hon. William H. Walls |
Prezista®(darunavir) |
RE42,889 |
Bristol-Myers Squibb Co. v. Sandoz Inc., 12-0787 (D. Del.) |
June 21, 2012 |
Hon. Richard G. Andrews |
Baraclude®(entecavir tablets) |
5,206,244 |
Pfizer Inc. v. Anchen Pharma., Inc., 12-0808 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Apotex, Inc., 12-0809 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Breckenridge Pharmaceitucal, Inc., 12-0810 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Lupin Ltd., 12-0811 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Mylan Pharma. Inc., 12-0812 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Roxane Labs. Inc., 12-0813 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Sandoz Inc., 12-0814 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Teva Pharma. USA Inc., 12-0815 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Watson Labs. Inc.—Florida, 12-0816 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Wockhardt Ltd., 12-0817 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Zydus Pharma. USA Inc., 12-0818 (D. Del.) |
June 22, 2012 |
Unassigned |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Sandoz Inc., 12-3880 (D.N.J.) |
June 25, 2012 |
Hon. Peter G. Sheridan |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Zydus Pharma. USA Inc., 12-3893 (D.N.J.) |
June 25, 2012 |
Hon. Peter G. Sheridan |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Watson Labs. Inc.—Florida, 12-61268 (S.D. Fla.) |
June 25, 2012 |
Hon. Robin S. Rosenbaum |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Pfizer Inc. v. Anchen Pharma., Inc., 12-5535 (C.D. Cal.) |
June 25, 2012 |
Hon. George H. King |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Galderma Labs. L.P. v. Actavis Mid Atlantic LLC, 12-2038 (N.D. Tex.) |
June 26, 2012 |
Hon. A. Joe Fish |
Epiduo®(adapalene and benzoyl peroxide gel) |
7,820,186 7,964,202 8,071,644 8,080,537 8,105,618 8,129,362 |
Pfizer Inc. v. Mylan Pharma. Inc., 12-0106 (N.D.W.V.) |
June 26, 2012 |
Hon. Irene M. Keeley |
Pristiq®(O-desmethylvenlafaxine succinate extended release tablets) |
6,673,838 |
Cumberland Pharma. Inc. v. Sagent Agila LLC, 12-0825 (D. Del.) |
June 26, 2012 |
Unassigned |
Acetadote®(acetylcysteine for injection) |
8,148,356 |
Novartis Pharma. Corp. v. Wockhardt USA LLC, 12-3967 (D.N.J.) |
June 27, 2012 |
Hon. Susan D. Wigenton |
Reclast®(zoledronic acid for injection) Zometa®(zoledronic acid for injection) |
7,932,241 8,052,987 |
Purdue Pharma L.P. v. Sandoz, Inc., 12-5082 (S.D.N.Y.) |
June 28, 2012 |
Unassigned |
OxyContin®(oxycodone hydrochloride extended release tablets) |
8,114,383 |
Purdue Pharma L.P. v. Teva Pharma. USA, Inc., 12-5083 (S.D.N.Y.) |
June 28, 2012 |
Unassigned |
OxyContin®(oxycodone hydrochloride extended release tablets) |
8,114,383 |
Endo Pharma. Inc. v. Noven Pharma., Inc., 12-0831 (D. Del.) |
June 29, 2012 |
Unassigned |
Lidoderm®(lidocaine transdermal) |
5,827,529 |
Alkermes Pharma Ireland Ltd. v. Intellipharmaceutics Corp., 12-0834 (D. Del.) |
June 29, 2012 |
Unassigned |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
6,228,398 6,730,325 |
Abbott Labs. v. Sandoz, Inc., 12-0836 (D. Del.) |
June 29, 2012 |
Unassigned |
Zemplar®(paricalcitol capsules) |
5,587,497 5,597,815 |
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.